Potentiation of a tumor cell susceptibility to autologous CTL killing by restoration of wild-type p53 function

Journal of Immunology

Volumn 170, Issue 12, 2003, Pages 5919-5926

  Thiery, Jérôme ^a   Dorotheé, Guillaume ^a   Haddada, Hedi ^a   Echchakir, Hamid ^a   Richon, Catherine ^a   Stancou, Rodica ^a   Vergnon, Isabelle ^a   Benard, Jean ^b   Mami Chouaib, Fathia ^a   Chouaib, Salem ^a  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; GENOMIC DNA; PROTEIN P21; PROTEIN P53; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADENOVIRUS; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL KILLING; CODON; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DNA SEQUENCE; EXON; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOLECULAR CLONING; MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIZATION; VIRUS RECOMBINANT;

EID: 0038620323     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.12.5919     Document Type: Article

References (42)

1. Chouaib, S., C. Asselin-Paturel, F. Mami-Chouaib, A. Caignard, and J. Y. Blay. 1997. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today 18:493.
2. Labarriere, N., E. Diez, M. C. Pandolfino, C. Viret, Y. Guilloux, S. Le Guiner, J. F. Fonteneau, B. Dreno, and F. Jotereau. 1997. Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription. J. Immunol. 158:1238.
3. Jager, E., M. Ringhoffer, M. Altmannsberger, M. Arand, J. Karbach, D. Jager, F. Oesch, and A. Knuth. 1997. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer 71:142.
4. Trapani, J. A. 1998. Dual mechanisms of apoptosis induction by cytotoxic lymphocytes. Int. Rev. Cytol. 182:111.
5. Henkart, P. A. 1994. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity 1:343.
6. Nagata, S., and P. Golstein. 1995. The Fas death factor. Science 267:1449.
7. Salvesen, G. S., and C. S. Duckett. 2002. IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 3:401.
8. Wajant, H. 2002. The Fas signaling pathway: more than a paradigm. Science 296:1635.
9. French, L. E., and J. Tschopp. 2002. Defective death receptor signaling as a cause of tumor immune escape. Semin. Cancer Biol. 12:51.
10. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323.
11. Oren, M. 1999. Regulation of the p53 tumor suppressor protein. J. Biol. Chem. 274:36031.
12. Hollstein, M., B. Shomer, M. Greenblatt, T. Soussi, E. Hovig, R. Montesano, and C. C. Harris. 1996. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res. 24:141.
13. Greenblatt, M. S., W. P. Bennett, M. Hollstein, and C. C. Harris. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855.
14. Iggo, R., K. Gatter, J. Bartek, D. Lane, and A. L. Harris. 1990. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335:675.
15. Levine, A. J. 1993. The tumor suppressor genes. Annu. Rev. Biochem. 62:623.
16. Vogelstein, B., D. Lane, and A. J. Levine. 2000. Surfing the p53 network. Nature 408:307.
17. Basu, A., and S. Haldar. 1998. The relationship between Bcl2, Bax and p53: consequences for cell cycle progression and cell death. Mol. Hum. Reprod. 4:1099.
18. Sheikh, M. S., and A. J. Fornace, Jr. 2000. Death and decoy receptors and p53-mediated apoptosis. Leukemia 14:1509.
19. Lowe, S. W., H. E. Ruley, T. Jacks, and D. E. Housman. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957.
20. Lowe, S. W. 1995. Cancer therapy and p53. Curr. Opin. Oncol. 7:547.
21. Asselin-Paturel, C., H. Echchakir, G. Carayol, F. Gay, P. Opolon, D. Grunenwald, S. Chouaib, and F. Mami-Chouaib. 1998. Quantitative analysis of Th1, Th2 and TGF-β1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int. J. Cancer 77:7.
22. Echchakir, H., I. Vergnon, G. Dorothee, D. Grunenwald, S. Chouaib, and F. Mami-Chouaib. 2000. Evidence for in situ expansion of diverse antitumor-specific cytotoxic T lymphocyte clones in a human large cell carcinoma of the lung. Int. Immunol. 12:537.
23. Ameyar, M., V. Shatrov, C. Bouquet, C. Capoulade, Z. Cai, R. Stancou, C. Badie, H. Haddada, and S. Chouaib. 1999. Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb. Oncogene 18:5464.
24. Zelphati, O., Y. Wang, S. Kitada, J. C. Reed, P. L. Felgner, and J. Corbeil. 2001. Intracellular delivery of proteins with a new lipid-mediated delivery system. J. Biol. Chem. 276:35103.
25. Pross, H. F., M. G. Baines, P. Rubin, P. Shragge, and M. S. Patterson. 1981. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin. Immunol. 1:51.
26. Echchakir, H., F. Mami-Chouaib, I. Vergnon, J. F. Baurain, V. Karanikas, S. Chouaib, and P. G. Coulie. 2001. A point mutation in the α-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res. 61:4078.
27. 1 checkpoint control. Cell 82:675.
28. Chouaib, S., J. Thiery, A. Gati, N. Guerra, M. E. Behi, G. Dorothée, F. Mami-Chouaib, D. Bellet, and A. Caignard. 2002. Tumor escape from killing: role of killer inhibitory receptors and acquisition of tumor resistance to cell death. Tissue Antigens 60:273.
29. Hermans, I. F., A. Daish, J. Yang, D. S. Ritchie, and F. Ronchese. 1998. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors. Cancer Res. 58:3909.
30. Romero, P., N. Gervois, J. Schneider, P. Escobar, D. Valmori, C. Pannetier, A. Steinle, T. Wolfel, D. Lienard, V. Brichard, et al. 1997. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J. Immunol. 159:2366.
31. Ghebranious, N., and L. A. Donehower. 1998. Mouse models in tumor suppression. Oncogene 17:3385.
32. Lee, J. M., and A. Bernstein. 1993. p53 mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci. USA 90:5742.
33. McIlwrath, A. J., P. A. Vasey, G. M. Ross, and R. Brown. 1994. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res. 54:3718.
34. Cai, Z., C. Capoulade, C. Moyret-Lalle, M. Amor-Gueret, J. Feunteun, A. K. Larsen, B. B. Paillerets, and S. Chouaib. 1997. Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function. Oncogene 15:2817.
35. Tergaonkar, V., M. Pando, O. Vafa, G. Wahl, and I. Verma. 2002. p53 stabilization is decreased upon NfκB activation: a role for NfκB in acquisition of resistance to chemotherapy. Cancer Cell 1:493.
36. Dorothee, G., M. Ameyar, A. Bettaieb, I. Vergnon, H. Echchakir, M. Bouziane, S. Chouaib, and F. Mami-Chouaib. 2001. Role of Fas and granule exocytosis pathways in tumor-infiltrating T lymphocyte-induced apoptosis of autologous human lung-carcinoma cells. Int. J. Cancer 91:772.
37. Medema, J. P., J. de Jong, T. van Hall, C. J. Melief, and R. Offringa. 1999. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 190:1033.
38. Djerbi, M., V. Screpanti, A. I. Catrina, B. Bogen, P. Biberfeld, and A. Grandien. 1999. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J. Exp. Med. 190:1025.
39. Sutton, V. R., J. E. Davis, M. Cancilla, R. W. Johnstone, A. A. Ruefli, K. Sedelies, K. A. Browne, and J. A. Trapani. 2000. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J. Exp. Med. 192:1403.
40. Selivanova, G., V. Iotsova, I. Okan, M. Fritsche, M. Strom, B. Groner, R. C. Grafstrom, and K. G. Wiman. 1997. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 3:632.
41. Bykov, V. J., N. Issaeva, A. Shilov, M. Hultcrantz, E. Pugacheva, P. Chumakov, J. Bergman, K. G. Wiman, and G. Selivanova. 2002. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8:282.
42. Yen, N., C. G. Ioannides, K. Xu, S. G. Swisher, D. D. Lawrence, B. L. Kemp, A. K. El-Naggar, R. J. Cristiano, B. Fang, B. S. Glisson, et al. 2000. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type P53 (Ad-p53). Cancer Gene Ther 7:530.